<SEC-DOCUMENT>0001171843-16-010307.txt : 20160525
<SEC-HEADER>0001171843-16-010307.hdr.sgml : 20160525
<ACCEPTANCE-DATETIME>20160525114806
ACCESSION NUMBER:		0001171843-16-010307
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20160523
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160525
DATE AS OF CHANGE:		20160525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		161673939

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_052516.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>WASHINGTON</B>,
D.C. 20549</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 16pt"><B>FORM 8-K</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>CURRENT REPORT</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>PURSUANT TO SECTION 13 OR 15(d)</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>OF THE SECURITIES EXCHANGE ACT
OF 1934</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Date of Report (Date of earliest event reported): May 23, 2016</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 18pt; text-align: center; text-indent: 0.2in; margin: 0pt 0"><B>BioCryst Pharmaceuticals, Inc.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"><I>(Exact Name of Registrant as
Specified in Charter)</I></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>000-23186</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>62-1413174</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(State or Other Jurisdiction</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(Commission</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(IRS Employer</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>of Incorporation)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>File Number)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>4505 Emperor Blvd., Suite 200<BR>
Durham, North Carolina 27703</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>(Address of Principal Executive Offices)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(919) 859-1302</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>(Registrant&rsquo;s telephone number, including area code)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">________________________________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>(Former Name or Former Address, if Changed Since Last Report)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">[_]<FONT STYLE="font-size: 10pt">&#9;Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">[_]<FONT STYLE="font-size: 10pt">&#9;Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">[_]<FONT STYLE="font-size: 10pt">&#9;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;210.14d-2(b))</FONT></P>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">[_]<FONT STYLE="font-size: 10pt">&#9;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">On May 23, 2016, the Compensation Committee of the Board of Directors
(the &ldquo;Board&rdquo;) of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) granted to all Company employees options
to purchase a total of 1,747,929 shares of the Company&rsquo;s common stock (the &ldquo;Retention Options&rdquo;) pursuant to the
Company&rsquo;s Amended and Restated Stock Incentive Plan (the &ldquo;Stock Incentive Plan&rdquo;). The Retention Options will
vest in equal annual installments over the four year period beginning on the grant date of May 23, 2016 and ending on the fourth
anniversary of the grant date. The number of Retention Options granted to each of the Named Executive Officers included in the
Company&rsquo;s proxy statement for the 2016 Annual Meeting of Stockholders (the &ldquo;Annual Meeting&rdquo;) is as follows:</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Employee</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Retention Options</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Jon Stonehouse</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">337,050</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">William P. Sheridan, MB BS</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Senior Vice President and Chief Medical Officer</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">148,302</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Senior Vice President and Chief Financial Officer</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">129,427</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Yarlagadda S. Babu</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Senior Vice President of Drug Discovery</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">129,427</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Lynne M. Powell</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Senior Vice President and Chief Commercial Officer</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">129,427</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">At the Annual Meeting held on May 23, 2016, the stockholders of the
Company approved, by the affirmative vote of a majority of the shares of common stock represented at the Annual Meeting in person
or by proxy and entitled to vote, a proposal to amend the Stock Incentive Plan to (i) increase the number of shares available for
issuance under the Stock Incentive Plan by 3,800,000 shares to 14,851,204 shares as of March 28, 2016 and (ii) provide for (A)
a minimum one-year vesting period for nearly all &ldquo;full-value&rdquo; future awards, (B) the elimination of &ldquo;single trigger&rdquo;
vesting of future awards upon a change in control when the awards are assumed or converted, and its replacement with &ldquo;double
trigger&rdquo; vesting protections in that event, and (C) express prohibitions on direct and indirect repricings of stock options
and stock appreciation rights. Effective following the Annual Meeting, the Board further amended the Stock Incentive Plan to increase
the number of options to purchase common stock granted automatically to non-employee directors pursuant to Article Four of the
Stock Incentive Plan. Pursuant to the Stock Incentive Plan, as so amended, newly appointed non-employee directors will receive
an automatic grant of 60,000 stock options, pro rated for the number of months remaining until the next scheduled annual meeting
of stockholders, and incumbent non-employee directors will receive an automatic grant of 30,000 stock options immediately after
each annual meeting of stockholders. All such stock options will vest monthly in equal portions until the next scheduled annual
meeting of stockholders.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">The description of the Stock Incentive Plan in this report does not
purport to be complete and is qualified by reference to the full text of the Stock Incentive Plan, a current copy of which is filed
as Exhibit 10.1 hereto and is incorporated herein by reference.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>Item&nbsp;5.07. Submission of Matters to a Vote of Security Holders.</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The Company&rsquo;s Annual Meeting was held on May 23, 2016 for the purpose of: (1) electing
two directors to serve for a term of three years and until a successor is duly elected and qualified; (2) ratifying the selection
of Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP as the Company&rsquo;s independent registered public accounting firm for 2016; and (3)
approving an amendment to the Stock Incentive Plan to (i) increase the number of shares available for issuance under the Stock
Incentive Plan by 3,800,000 shares to 14,851,204 shares as of March 28, 2016 and (ii) provide for (A) a minimum one-year vesting
period for nearly all &ldquo;full-value&rdquo; future awards, (B) the elimination of &ldquo;single trigger&rdquo; vesting of future
awards upon a change in control when the awards are assumed or converted, and its replacement with &ldquo;double trigger&rdquo;
vesting protections in that event, and (C) express prohibitions on direct and indirect repricings of stock options and stock appreciation
rights.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The nominees for director were elected by the following votes:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="6" STYLE="width: 70%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 25%"><FONT STYLE="font-size: 10pt"><U>FOR</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 25%"><FONT STYLE="font-size: 10pt"><U>WITHHELD</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Fred E. Cohen, M.D., D.Phil.</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>23,838,523</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>11,123,584</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Kenneth B. Lee, Jr.</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>34,786,610</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>175,497</U></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="background-color: white">In addition, there were 25,642,055 broker non-votes
for each director.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The proposed ratification of the selection of Ernst &amp; Young LLP as the Company&rsquo;s
independent registered public accounting firm for 2016 was approved by the following votes:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="6" STYLE="width: 70%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">FOR</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 30%"><FONT STYLE="font-size: 10pt"><U>60,362,604</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">AGAINST</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>206,672</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ABSTAIN</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>34,886</U></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0; background-color: white">The proposed amendment to the Company&rsquo;s
Stock Incentive Plan to increase the number of shares available for issuance and to provide for (A) a minimum one-year vesting
period for nearly all &ldquo;full-value&rdquo; future awards, (B) the elimination of &ldquo;single trigger&rdquo; vesting of future
awards upon a change in control when the awards are assumed or converted, and its replacement with &ldquo;double trigger&rdquo;
vesting protections in that event, and (C) express prohibitions on direct and indirect repricings of stock options and stock appreciation
rights:</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="6" STYLE="width: 70%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">FOR</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 30%"><FONT STYLE="font-size: 10pt"><U>32,786,134</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">AGAINST</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>2,010,621</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ABSTAIN</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>165,352</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">BROKER NON-VOTES</FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>25,642,055</U></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">There was no other business voted upon at the Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Registration Statement on Form S-8 filed on May 23, 2016 (File No. 333-211529)).</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.2in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="vertical-align: middle; text-align: left">Dated: May 25, 2016</td>
    <td colspan="2" style="font-weight: bold; vertical-align: middle; text-align: left">BioCryst Pharmaceuticals, Inc.</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: middle; text-align: left; width: 50%">&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left; width: 3%">&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left; width: 30%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 17%">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left">By:&nbsp;&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left; border-bottom: Black 1pt solid">/s/ Alane Barnes</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left">Alane Barnes</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: middle">&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</td>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">Vice President, General Counsel,</td></tr>
<tr>
    <TD STYLE="vertical-align: middle">&nbsp;</td>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</td>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">and Corporate Secretary</td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.2in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT INDEX</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Registration Statement on Form S-8 filed on May 23, 2016 (File No. 333-211529)).</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
